Benay YILDIRIM, Süleyman BÜYÜKBERBER, Defne AKPINAR, Umut DEMİRCİ, Meltem BAYKARA, Önder TONYALİ, Uğur COŞKUN, Mustafa BENEKLİ

Mandibuler osteonekroz: Olgu sunumu

Prostat kanseri erkeklerde en sık rastlanan ve en sık kemik metastazı yapan kanserdir. Ancak mandibula metastazınadirdir. Mandibuler osteonekroz ise daha güçlü bifosfonatların kullanıma girmesinden sonra tanımlanmış bir antitedir. Bu olgu sunumunda yaygın kemik metastazı ile başvuran hastaya zolendronik asit tedavisi sırasında kemikmetastazlarında ilerleme ile birlikte yeni ortaya çıkan mandibular lezyon için radyoterapi uygulanmıştır. Semptomlarında artış olan hastaya biyopsi ile zolendronik aside bağlı osteonekroz tanısı konulmuştur.(Gazi Med J 2011; 22: 88-90)

Mandibular osteonecrosis: Case report

Prostate cancer is the most common cancer in men. Although bone metastases occur very frequently, mandibularmetastasis is very rare in prostate cancer. Mandibular osteonecrosis is a new entity described after potent bisphos-phonate treatment. In this case report, a patient who presented with widespread bone metastases was treated withradiotherapy for new development of a mandibular lesion along with progression of the other bone metastases during zolendronic acid treatment. When he was admitted to our hospital with increased symptoms, the diagnosis ofmandibular osteonecrosis was established by biopsy. (Gazi Med J 2011; 22: 88-90)

PDF

___

1. Carlin BI, Andriole GL. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-94.
2. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, et al. Alendronate distrubuted on bone surfaces inhibites osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995; 16: 235-45.
3. Licata AA. Discovery, clinical development, and therapeutic uses of BPs. Ann Pharmacother 2005; 9: 668-77.
4. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-61.
5. Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA 2006; 295: 2833-6.
6. Oh HK, Chambers MS, Garden AS, Lim HJ, Park HJ. Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg 2009; 67: 1378-86.
7. D’Silva NJ, Summerlin DJ, Cordell KC, Abdelsayed RA, Tomich CE, Hanks CT, et al. Metastatic tumors in the jaws A retrospective study of 114 cases. J Am Dent Assoc 2006; 137: 1667-72.
8. Sánchez Aniceto G, García Peñín A, de la Mata Pages R, Montalvo Moreno JJ. Tumors metastatic to the mandible: analysis of nine cases and review of the literature. J Oral Maxillofac Surg 1990; 48: 246-51.
9. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tu-mours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol 2008; 44: 743-52.
10. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580-7.
11. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of BP-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-23.
12. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 2005; 353: 99-102.
13. Ferreti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, et al. Zolendronic acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35-43.
14. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002; 32: 94-124.